Quick Answer
Evommune, Inc. reported Total Revenue of $13.00 million for fiscal year 2025.
Evommune, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Revenue | $13.00M +85.7% |
$7.00M | — |
| Revenue (ASC 606) | $13.00M +85.7% |
$7.00M | — |
| Net Income | -$68.87M -3.1% |
-$66.81M | — |
| Diluted EPS | -$11.22 +75.2% |
-$45.29 | — |
| Total Assets | $224.95M +195.8% |
$76.06M | — |
| Cash and Equivalents | $44.06M +171.1% |
$16.25M | — |
| Stockholders Equity | $205.57M +242.5% |
-$144.24M -85.6% |
-$77.71M |
| R&D Expense | $74.04M +15.3% |
$64.24M | — |
| Operating Income | -$81.07M -15.8% |
-$70.01M | — |
| Shares Outstanding | 31.52M +1932.0% |
1.55M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $10.00M | — | — |
| Revenue (ASC 606) | September 30, 2025 | $10.00M | — | — |
| Net Income | September 30, 2025 | -$12.47M | +21.6% | +21.6% |
| Diluted EPS | September 30, 2025 | -$8.07 | +22.9% | +22.9% |
| Total Assets | September 30, 2025 | $84.54M | — | +11.2% |
| Cash and Equivalents | September 30, 2025 | $26.82M | +47.8% | +65.0% |
| Stockholders Equity | September 30, 2025 | -$183.14M | -49.5% | -7.0% |
| R&D Expense | September 30, 2025 | $19.64M | +47.8% | +47.8% |
| Operating Income | September 30, 2025 | -$13.33M | +19.3% | +19.3% |
| Shares Outstanding | September 30, 2025 | 1.55M | — | +0.2% |
- Evommune, Inc. reported Total Revenue of $13.00 million for fiscal year 2025.
- Evommune, Inc. showed an increase of +85.7% in Total Revenue compared to the prior fiscal year.
- Evommune, Inc. reported Revenue (ASC 606) of $13.00 million for fiscal year 2025.
- Evommune, Inc. showed an increase of +85.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Evommune, Inc. reported Net Income of -$68.87 million for fiscal year 2025.
- Evommune, Inc. showed a decrease of -3.1% in Net Income compared to the prior fiscal year.
- Evommune, Inc. reported Diluted EPS of $11.22 per share (loss) for fiscal year 2025.
- Evommune, Inc. showed an increase of +75.2% in Diluted EPS compared to the prior fiscal year.
- Evommune, Inc. reported Total Assets of $224.95 million for fiscal year 2025.
- Evommune, Inc. showed an increase of +195.8% in Total Assets compared to the prior fiscal year.
- Evommune, Inc. reported Cash and Equivalents of $44.06 million for fiscal year 2025.
- Evommune, Inc. showed an increase of +171.1% in Cash and Equivalents compared to the prior fiscal year.
- Evommune, Inc. reported Stockholders Equity of $205.57 million for fiscal year 2025.
- Evommune, Inc. showed an increase of +242.5% in Stockholders Equity compared to the prior fiscal year.
- Evommune, Inc. reported R&D Expense of $74.04 million for fiscal year 2025.
- Evommune, Inc. showed an increase of +15.3% in R&D Expense compared to the prior fiscal year.
- Evommune, Inc. reported Operating Income of -$81.07 million for fiscal year 2025.
- Evommune, Inc. showed a decrease of -15.8% in Operating Income compared to the prior fiscal year.
- Evommune, Inc. reported Shares Outstanding of 31.52 million shares for fiscal year 2025.
- Evommune, Inc. showed an increase of +1932.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: